BACKGROUND: Depot formulations prolong the analgesic effect of local anesthetics and reduce peak plasma drug concentration. This allows for safer administration of larger doses of local anesthetics, which further prolongs the duration of analgesic effect. We previously reported the development of large multivesicular vesicles (LMVVs) remotely loaded with bupivacaine (LMVV liposomal bupivacaine) and demonstrated a Ͼ5-fold prolongation of analgesic effect in animals and humans. In this study, we present pharmacokinetic data of LMVV liposomal bupivacaine in humans. METHODS: Healthy volunteers received subcutaneous injections of 20 mL plain 0.5% bupivacaine and, 1 week later, 20 mL of 2% LMVV liposomal bupivacaine in a prospective, open-label, crossover, controlled study. RESULTS: Eight subjects were studied. No subjective side effects of local anesthetics were observed. The maximal plasma concentration and the time to achieve maximal plasma concentration were assessed by modeling plasma concentration-time profiles. Maximal plasma concentration was not significantly different between groups (0.87 Ϯ 0.45 g/mL and 0.83 Ϯ 0.34 g/mL for plain and liposomal bupivacaine, respectively; P ϭ not significant, 0.83). These values are well below the putative toxic plasma concentration of 2 to 4 g/mL. Time to achieve maximal plasma concentration was 7-fold greater for the liposomal preparation (262 Ϯ 149 minutes vs 37.5 Ϯ 16 minutes, P Ͻ 0.01). CONCLUSIONS: Peak plasma bupivacaine concentrations were not different in the 2 groups, despite a 4-fold increase in total bupivacaine dose administered in the novel liposomal preparation. The delayed elimination and prolonged redistribution of liposomal bupivacaine to plasma is compatible with the depot-related slow-release effect leading to the prolonged pharmacodynamic effect previously reported.
R apid systemic absorption of low-molecular-weight local anesthetics from their site of administration leads to 2 important limitations for local anesthetic use: (1) short duration of analgesic effect after bolus dose administration, and (2) limitations on the maximal dose that may be safely administered, with the risk of systemic toxicity if these limits are exceeded. One approach that has been attempted to circumvent both these constraints is the development of depot formulations or devices that are designed to remain at the site of injection and release drug slowly over time at a dose sufficient to induce analgesia. 1 The benefits of such an approach are (1) a prolonged analgesic effect and (2) reduction of the plasma peak drug concentration, 2,3 allowing the safe administration of larger doses, which further prolongs the duration of analgesia.
Depot formulations that have been described include liposomes, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] microspheres, 14 -17 polymer matrices, 18, 19 and lipid depots. 20, 21 Each has its advantages and disadvantages, but none is, as yet, commercially available. Although liposomes have been widely reported in both animals 2, 3, 11, 12, 21, 22 and humans, 10, 23, 24 the clinical utility of these preparations has been limited by their low drug-tophospholipid (D/PL) ratio, requiring the administration of a large lipid load to achieve the desired analgesic effect. We reported the development of a liposomal bupivacaine preparation based on large multivesicular vesicles (LMVVs) with a high D/PL mole ratio of 1.8, 10 5-fold greater than that of earlier preparations. 11 Release of bupivacaine from the LMVVs is by diffusion of the unprotonated (uncharged) species of bupivacaine, which is an amphipathic weak base with a relatively high octanol-tobuffer partition coefficient. 10 This process is pH-dependent reflecting the level of the uncharged species.
In rats, we demonstrated that LMVV bupivacaine was associated with a prolonged antinociception, 12 reduced plasma bupivacaine concentrations, 12 and an 8-fold increase in the lethal dose (LD 50 ) (565 mg/kg compared with 71 mg/kg) compared with plain bupivacaine controls. 4 In humans, the administration of 0.5%, 1%, and 2% LMVV bupivacaine provided 19, 38, and 48 hours of analgesia to pinprick, respectively, compared with 1 hour for the standard 0.5% bupivacaine control. 10 The maximal recommended dose of bupivacaine for peripheral administration is 2.5 mg/kg. 25 After animal studies 12 and preliminary dose-escalating pilot studies in humans (see below), we administered 20 mL of 2% LMVV liposomal bupivacaine, giving 400 mg bupivacaine per patient, which is more than twice the maximal recommended dose for an average 70-kg patient using plain bupivacaine. The objective of the current study was to examine whether administration of this high-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates sustained release of the drug at the site of injection, without exposing patients to toxic plasma concentrations. In this article, we report pharmacokinetic data in humans of the LMVV liposomal bupivacaine and compare them with those of standard bupivacaine.
METHODS
This pharmacokinetic study was approved for volunteers by the IRB of Hadassah Hospital* and by the Israel Ministry of Health. Written informed consent was obtained from all volunteers.
Subjects
All subjects were interviewed for their medical history, underwent a physical examination, and had a resting 12-lead electrocardiogram. Subjects were eligible for enrollment if they were 18 to 45 years old, ASA physical status I, within 20% of ideal body weight (according to body mass index tables of the National Heart, Lung, and Blood Institute), and had not received any medications within 1 week of the start of the studies.
Pharmacokinetic Study Protocol
We designed a prospective, open-label, crossover, controlled study to compare the pharmacokinetic characteristics of subcutaneously administered bupivacaine as a 0.5% plain solution or as a 2% bupivacaine LMVV liposomal dispersion. On days 1 and 8, 20 mL of drug (10 mL into each flank) was injected subcutaneously via a 22-gauge needle. On day 1, the study drug was 0.5% plain bupivacaine, and on day 8, the study drug was 2% LMVV liposomal bupivacaine; this order of injection was determined by the prolonged elimination time for liposomal bupivacaine that had been reported in animals [2] [3] [4] 12 and in humans. 23 For the first hour after drug administration, subjects were monitored (continuous 3-lead electrocardiogram and noninvasive arterial blood pressure) in a postanesthesia care unit.
Preparation of Liposomes
The LMVV liposomal bupivacaine used in this study was identical to that described previously, 10 and the preparation and in vitro characteristics have been described in detail. 10 The bupivacaine-loaded LMVVs had a D/PL ratio of 1.8, which was achieved using the remote (active) loading of high concentrations of bupivacaine by means of an intraliposome-high/extraliposome-medium-low transmembrane ammonium sulfate gradient into LMVVs. LMVV liposomal bupivacaine is characterized by a large intraliposomal multicompartment aqueous phase with a high capacity for bupivacaine loading. As described in previous reports, 10, 11 the product was evaluated for size distribution (2439 Ϯ 544 nm) by photon correlation spectroscopy, bupivacaine concentration in all preparations including control was confirmed by high-performance liquid chromatography, sterility was confirmed by lack of growth after 2 weeks in aerobic and anaerobic culture media, and the lack of pyrogenicity was confirmed using the limulus test. 10, 11 Drug-release characteristics have been reported previously. 10 LMVV liposomal bupivacaine was diluted in normal saline to yield formulations of 0.5%, 1.0%, 1.5%, and 2% bupivacaine, which were stored at 4°C and dispensed by a pharmacist. Standard 0.5% bupivacaine (5 mg/mL; Abbott Laboratories, North Chicago, IL) was used as control.
Determination of Plasma Bupivacaine Concentration
After plain bupivacaine administration, blood was sampled to determine the plasma bupivacaine concentration at baseline and at 15, 30, 45, 60, 90, 120, 180, and 240 minutes. After liposomal bupivacaine administration, blood was sampled at baseline and at 15, 30, 45, 60, 90, 120, 180, 240, 480, 1440, 1920 , and 2880 minutes in all subjects. Venous blood was sampled via a 16-gauge IV catheter in the forearm after the aspiration of 10 mL of dead space. Sampled blood was collected into heparinized vials. Plasma was immediately separated from blood cells by low-speed centrifugation, and samples of 2 mL plasma were labeled and stored frozen at Ϫ20°C until chromatographic analysis. Bupivacaine was extracted from plasma samples and analyzed using high-performance liquid chromatography, as described previously. 11 Mepivacaine was used as an internal standard. The limit of quantification of bupivacaine plasma concentration was 5 ng/mL.
Pharmacokinetic Assessment
The concentration-time data obtained in the study were analyzed by the noncompartmental approach. The following pharmacokinetic parameters were calculated: peak plasma bupivacaine concentration (Cmax), the time to achieve the maximal plasma concentration (Tmax), the area under bupivacaine time-concentration curve extrapolated *The doses used in this study were based on a separate IRB-approved pilot dose-escalating safety study in which 4 groups of 3 subjects received 20 mL (10 mL in each flank) of 0.5%, 1%, 1.5%, and 2% LMVV liposomal bupivacaine. In that study, plasma bupivacaine concentrations did not reach the putative toxic range in any patient.
to infinity (AUC), and the terminal half-life. In addition, the concentration-time data of bupivacaine after IV administration was obtained from a previously published study 26 (as described in detail in the Appendix), which allowed the calculation of absolute bioavailability values of bupivacaine after subcutaneous administration. The calculations were performed using WinNonlin software (WinNonlin version 4.5, Pharsight Corporation, Mountain View, CA).
Statistical Analysis
Normally distributed data are presented as mean Ϯ SD; nonnormally distributed data are presented as median (95% confidence interval). In view of the small size of the data set, an appropriate nonparametric test (Wilcoxon signed rank test) was used to detect significant differences between the pharmacokinetic parameters for 0.5% plain bupivacaine and 2% liposomal bupivacaine. Significance was assumed at P Յ0.05.
RESULTS
Eight subjects were studied. The mean age was 33 years (range, 26 -44 years), mean height was 176 cm (range, 165-185 cm), and mean weight was 78 kg (range, 60 -110 kg). No subject reported symptoms of local anesthetic toxicity. Plasma bupivacaine concentration did not exceed 2 g/mL in any of the subjects. All data sets were normally distributed and were expressed as mean and SD.
Pharmacokinetic Parameters
The plasma bupivacaine concentration at time intervals after subcutaneous administration of 20 mL of 0.5% plain bupivacaine and 20 mL of 2% LMVV liposomal bupivacaine is shown in Figure 1 , a-c. The pharmacokinetic parameters for the plain and LMVV liposomal bupivacaine after subcutaneous administration are listed in Table 1 . The Cmax was not significantly different between groups. The highest measured plasma bupivacaine concentration for any subject was 1.51 g/mL, recorded 30 minutes after the administration of 0.5% plain bupivacaine (Fig. 1b) . The highest measured plasma bupivacaine concentration for an individual subject in the liposomal bupivacaine group was 1.36 g/mL, recorded at 90 minutes (Fig. 1c ). Modeled Cmax data for different individuals ranged from 0.4 to 1.5 g/mL and 0.3 to 1.3 g/mL for plain and liposomal bupivacaine, respectively. These values are well below the putative toxic plasma concentration reported in humans of 2 to 4 g/mL. 28 Comparing the plain and liposomal bupivacaine preparations, there was no difference in the modeled Cmax, despite a 4-fold increase in total bupivacaine dose in the liposomal preparation whereas the modeled Tmax was 7-fold greater in the liposomal preparation (262 Ϯ 149 minutes vs 37.5 Ϯ 16 minutes in the plain bupivacaine preparation, P Ͻ 0.01). The extrapolated area at the tail of the plasma bupivacaine concentration-time curve was 28.2% Ϯ 12.6% for plain bupivacaine and 26.3% Ϯ 22.3% for LMVV liposomal bupivacaine. The calculated absolute bioavailability from subcutaneous injection was 87% and 204% for plain and liposomal bupivacaine, respectively. The terminal half-life of plain bupivacaine after IV administration obtained from the literature 26 (67.3 minutes) was shorter than the half-life after subcutaneous administration of plain (131 Ϯ 58 minutes) or liposomal bupivacaine (1294 Ϯ 860 minutes).
DISCUSSION
We report pharmacokinetic data in humans using clinically relevant doses of liposomal bupivacaine remotely loaded into LMVV liposomal bupivacaine. The pharmacokinetic study showed no difference in Cmax between standard and liposomal bupivacaine, despite a 4-fold increase in bupivacaine dose for the liposomal preparation.
The threshold plasma concentrations of bupivacaine that are reported to be associated with the onset of central nervous system toxicity are in the range of 2 to 4 g/mL. 27, 28 We demonstrated a Cmax range of 0.4 to 1.4 g/mL for 20 mL of 2% LMVV liposomal bupivacaine, a plasma concentration range that is well below the reported putative toxic plasma concentration.
Rapid local redistribution and systemic absorption of plain local anesthetics curtails the local anesthetic effect and increases plasma drug concentration, which may lead to systemic toxicity. Slow-release local anesthetics prolong drug action at the effect site, both prolonging anesthetic effect and reducing systemic absorption. The liposomal bupivacaine preparation had properties typical of slowrelease formulations, resulting in 7-fold prolongation of Tmax. Although we were unable to measure injection-site concentrations of bupivacaine delivered via the liposomal preparation in this study, the delayed redistribution of liposomal bupivacaine to plasma serves as a good indication for the depot-related slow-release profile of bupivacaine delivered locally via liposomes and is compatible with the prolonged pharmacodynamic effect previously reported in animals 2-4 and humans. 10 Availability of the concentration-time data for bupivacaine after IV administration from previously published research 26 allowed us to calculate the extent of absorption of subcutaneously administered bupivacaine. The plain bupivacaine formulation demonstrated a high absolute bioavailability of approximately 87%. Interestingly, the apparent absolute bioavailability of the liposomal formulation was Ͼ200%. The simple comparison of the AUC and the apparent difference in bioavailability for plain and liposomal bupivacaine suggests that the elimination pharmacokinetics of liposomal bupivacaine is not linear with respect to dose in a simple aqueous media. This finding is most likely to be attributed to a direct absorption of a fraction of liposomes (presumably the smallest liposomes Ͻ400 nm) into the systemic circulation (probably via lymphatic and/or venous drainage). The presence of even a small amount of liposomes in the circulation would reduce the systemic clearance of bupivacaine and result in the increased AUC that was observed in the study. The processes that we hypothesize to occur are summarized in Figure 2 .
To more thoroughly investigate the absorption kinetics of plain bupivacaine after subcutaneous administration, deconvolution was performed using the pharmacokinetic parameters of IV bupivacaine in a previously published study obtained by compartmental analysis (as described in the Appendix). As can be seen from Figure 3 and in the Appendix, Ͼ50% of the dose was absorbed into the systemic circulation during the first hour after subcutaneous administration of plain bupivacaine. Because systemic clearance of the drug after administration of the liposomal formulation is apparently altered, the IV data of plain bupivacaine cannot be used to calculate either the extent of absorption or the absorption function for the liposomal formulation. The pharmacokinetic parameters required for deconvolution could be obtained by performing a separate study of IV administered liposomal bupivacaine formulation; however, this would not contribute directly to the aim of our current study, which is to show the lack of systemic toxic levels after subcutaneous administration of high-dose liposomal bupivacaine.
In a previous study, we demonstrated a prolonged analgesic effect after the administration of 0.5 mL of 2% liposomal bupivacaine for 48 hours. 10 In that study, we reported a double-blind, randomized crossover trial in which the efficacy of LMVV liposomal bupivacaine was studied in volunteers. The volunteers received simultaneous intradermal injections at 4 different skin locations with 0.5 mL each of standard (nonliposomal) 0.5% bupivacaine and of 0.5%, 1%, and 2% bupivacaine in the form of LMVV liposomal bupivacaine. 10 The 0.5%, 1%, and 2% LMVV liposomal bupivacaine provided 19, 38, and 48 hours of analgesia to pinprick, respectively, compared with 1 hour for the standard 0.5% bupivacaine control. However, the simultaneous, multiple-site, crossover design of that study and the miniscule volumes of local anesthetic used made pharmacokinetic assessment impossible.
Although we report the AUC for the plasma bupivacaine concentration-time curve, this is a less useful measure of drug efficacy or side effects in this scenario, because drug efficacy is dependent on bupivacaine concentration at the site of injection (and not on plasma bupivacaine concentration), whereas side effects are dependent on the maximal plasma bupivacaine concentration (Cmax) (and not on the AUC of the plasma bupivacaine concentrationtime curve). Furthermore, the AUC data in this study were extrapolated beyond 15%, and therefore may be inaccurate.
Measurement of plasma bupivacaine concentrations at intervals in the elimination tail would have enabled an assessment of the bioavailability of plain and liposomal bupivacaine, administered subcutaneously; however, this was not the primary objective of this study.
The order of drug administration was not randomized in this study because the previously reported prolonged elimination time of liposomal bupivacaine in both animals [2] [3] [4] 12 and in humans 23 suggested that we would have had to wait for an inordinately long period of time for complete washout of liposomal bupivacaine before administration of the aqueous drug. Indeed, the plasma bupivacaine concentrations at baseline were negligible on both days. Although the order of drug administration was not performed in a blinded manner, the technician performing the assays was blinded. Consequently, this does not present a serious limitation to the conclusions of this study.
The sustained release of bupivacaine from microparticles has been associated with myotoxicity after IM injection. 29 Before advocating the use of LMVV liposomal bupivacaine for peripheral or neuraxial blockade, the lack of neurotoxicity from either the prolonged local anesthetic action or from the liposomal preparation must be demonstrated.
This study demonstrates that the liposomal formulation allows the administration of a 4-fold increase in bupivacaine, without increasing peak plasma concentrations or the risk of systemic toxicity, and that the redistribution of drug to plasma is extended over a time range compatible with the prolonged analgesic effect previously described.
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APPENDIX
In our study, pharmacokinetic data after IV administration of bupivacaine were not evaluated because we compared 2 formulations both administered via the subcutaneous (SC) route. To obtain the absorption function for SC bupivacaine, we needed to know the distribution and elimination of the compound after IV administration as a reference control. We performed a literature search to find a suitable data series to serve as an IV control. Information on systemic pharmacokinetics of IV bupivacaine is limited; however, we found a reference for a study that compared pharmacokinetics of levobupivacaine and bupivacaine in volunteers after IV administration. 26 In that study, 12 healthy male volunteers received 40 mg bupivacaine as an 8-minute IV infusion. The mean concentration-time data were captured by computer digitalization. The data were adequately described by the classical 2-compartment pharmacokinetic model using a uniform weighting scheme (where the plasma concentration [C] is described by the following equation: C ϭ A ⅐ e Ϫ␣t ϩ B ⅐ e Ϫ␤t ). Figure 3 shows the original data set together with the prediction provided by the model. The pharmacokinetic parameters were as follows: ␣ ϭ 0.115 min Ϫ1 , ␤ ϭ 0.0106 min Ϫ1 , A ϭ 1.50 g/mL, B ϭ 0.585 g/mL, and the volumes of the central and the peripheral compartments were 19.1 and 26.5 L, respectively. These parameters were used to describe the unit impulse response function to perform the numerical deconvolution on the concentration-time profile of plain bupivacaine from this study. Figure 4 presents the percent of the absorbed dose as a function of time for plain bupivacaine.
Deconvolution could not be used to estimate the absorption function of liposomal bupivacaine because linearity with respect to dose is apparently violated in this case.
